Venetoclax is an FDA-approved oral Bcl-2 inhibitor showing promise in restoring mitochondrial apoptosis in chronic lymphocytic leukemia (CLL) cells [1396]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.